Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window.

5 Jun 2013

Taking blood thinners before minor procedures safe for stroke patients

Many patients who have experienced strokes or mini strokes take blood thinners such as aspirin or warfarin (Coumadin) to reduce the risk of blood clots that can cause strokes.

30 May 2013

New AAN guideline provides direction for use of blood thinners during surgery

A new guideline from the American Academy of Neurology will help people who take blood thinners decide whether or not to take them during surgery or other medical procedures.

28 May 2013

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Astellas Pharma Inc. and Medivation, Inc. today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.

24 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

Study shows patient satisfaction from a pharmacy program

As hospitals look for ways to improve patient satisfaction and boost their Medicare reimbursement, a Henry Ford Hospital study found that an inpatient pharmacist-directed anticoagulation service might be an unexpected opportunity.

13 May 2013

Operating without interrupting warfarin treatment during cardiac device surgery reduces hematomas

A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care.

10 May 2013

Implantation of new mechanical heart valve reduces anticoagulation therapy in AVR patients

For more than 40 years, patients under 65 years of age requiring heart valve replacement have had to choose between a mechanical valve that offers life-long durability but requires aggressive warfarin anticoagulation or a biological (cow or pig) valve that will wear out in 10-20 years but does not require anticoagulation.

7 May 2013

Kcentra gets FDA approval for adults with acute major bleeding

The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding.

30 Apr 2013

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.

30 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

HUGO recognizes Dr. Patrick Tan for research on genomic profiles of Asian cancers

Dr Patrick Tan from A*STAR's Genome Institute of Singapore has received the 2013 Chen New Investigator Award from the international Human Genome Organisation.

19 Apr 2013

Study: Pradaxa drug may increase risk and severity of viral infections

A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults.

2 Apr 2013

University of Michigan Stroke Program study examines use of tPA in stroke patients

Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.

14 Mar 2013

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.

11 Mar 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

Warfarin News and Research

Further Reading